糖皮质激素性骨质疏松发病机制与预防  

Pathogenesis and Prevention of Glucocorticoid-induced Osteoporosis

作　　者：方楚玲[1] 田京[1] 

机构地区：[1]南方医科大学珠江医院骨科,广州510282

出　　处：《医学综述》2014年第20期3718-3720,3723,共4页Medical Recapitulate

基　　金：广东省科技计划资助项目(2011B031800147)

摘　　要：骨质疏松症是与年龄相关的一种全身性疾病,也是有关骨骼的一个世界性健康问题,其特征性表现为骨量减少及骨质的微观结构发生退化,常见并发症为各种脆性骨折。糖皮质激素(GC)广泛应用于临床众多领域,其主要不良反应是骨质疏松并增加骨折风险。并非大剂量应用GC才会导致骨质疏松,老年人及开始GC治疗前即存在骨矿密度低的患者,骨量丢失更加明显,更易导致骨折的发生。Osteoporosis is a systemic disease related to age,which is also a global health issue,featured with bone mass loss and degeneration of the bone microstructure,and the common complications are various brittle fractures.Glucocorticoids are widely used in clinical fields,the main side effects of which are osteoporosis and increased fracture risk.Not only a large dose of glucocorticoids would lead to osteoporosis,elderly and those with low bone mineral density before initiating glucocorticoid therapy are more likely to have bone loss and fractures.

关 键 词：糖皮质激素性骨质疏松 发病机制 预防 

分 类 号：R683[医药卫生—骨科学]